Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Both the India and GCC entities will be operated by separate dedicated management teams
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Yesafili, received marketing authorization approval from the European Commission for the European Union
Subscribe To Our Newsletter & Stay Updated